News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

HealthTronics Launches New Line of Slimline Cryoprobes for Use With Its Endocare® Cryocare® Systems


11/2/2012 10:16:49 AM

AUSTIN, Texas, Nov. 2, 2012 /PRNewswire/ -- HealthTronics Inc., an Endo Health Solutions company (Nasdaq: ENDP), today announced that its subsidiary, Endocare Inc., has launched a new line of right angle slimline cryoprobes for use with the Endocare® Cryocare® Systems.

The new cryoprobes feature a slim ergonomic handle designed to improve the ability of clinicians to place these probes within the limited confines of interventional radiology procedure suites. Designed to provide increased maneuverability, the tubing attached to the new cryoprobes is lighter and more flexible than existing cryoprobes' tubing.

"By incorporating feedback from interventional radiologists while designing this line of slimline cryoprobes, we're bringing to market these advanced cryoprobes," said Mark Rooney, Vice President and General Manager of Oncology Solutions, HealthTronics. "Cryoablation continues to grow as a treatment option for multiple applications, and we want to provide our customers with the tools and technology they need to best treat their patients. We are proud to introduce this new line of next generation cryoprobes."

About Cryoablation and the Endocare® Cryocare® Systems
Cryoablation, also known as cryotherapy, uses proven, state-of-the-art technology to destroy cancerous tissue by using extremely cold temperatures that freeze affected cells. Endocare remains the market leader in this category, and, as a wholly owned subsidiary of HealthTronics, is able to supply the broadest offerings of customer solutions available for cryoablation. For more information, go to www.healthtronics.com or call 855-ENDOCARE.

Important Safety Information about Endocare Cryotherapy
This treatment is not for everyone. Patients should consult their cancer care team to decide whether cryoablation is right for them. Patients who receive cryoablation should be carefully monitored after cryoablation to detect recurrence and treat as necessary. Only qualified, trained personnel should operate the Endocare® Cryocare® Systems. Physicians offering cryoablation must be trained to use the systems.

About HealthTronics
HealthTronics Inc. is a national provider of urological and interventional oncology services and products for more than 20 years. Headquartered in Austin, Texas, with anatomical pathology laboratories in three states, the company provides the most advanced technology and premiere support systems to urologists, interventional radiologists, hospitals, surgery centers and clinics across the United States. HealthTronics is an operating company of Endo Health Solutions Inc. (Nasdaq: ENDP), a diversified healthcare company that is dedicated to improving care through a combination of branded products, generics, devices, technology and services. Learn more at www.endo.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in Endo Health Solutions Inc.'s Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect future financial results and could cause actual results to differ materially from those expressed in forward-looking statements contained in Endo Health Solutions Inc.'s Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE HealthTronics Inc.


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES